Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by GHP Investment Advisors Inc.

GHP Investment Advisors Inc. raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 58.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 50,884 shares of the company's stock after purchasing an additional 18,819 shares during the quarter. GHP Investment Advisors Inc.'s holdings in Teva Pharmaceutical Industries were worth $782,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Whalen Wealth Management Inc. purchased a new stake in Teva Pharmaceutical Industries in the first quarter valued at $404,000. Cambridge Investment Research Advisors Inc. boosted its holdings in Teva Pharmaceutical Industries by 97.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 84,263 shares of the company's stock valued at $1,295,000 after purchasing an additional 41,600 shares during the last quarter. Retirement Systems of Alabama purchased a new stake in Teva Pharmaceutical Industries in the first quarter valued at $6,167,000. Essex Savings Bank boosted its holdings in Teva Pharmaceutical Industries by 13.5% in the first quarter. Essex Savings Bank now owns 16,770 shares of the company's stock valued at $258,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Bfsg LLC boosted its holdings in Teva Pharmaceutical Industries by 7.8% in the first quarter. Bfsg LLC now owns 10,960 shares of the company's stock valued at $168,000 after purchasing an additional 790 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on TEVA. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 target price on the stock. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price on the stock. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $21.00 to $23.00 in a research note on Monday, May 12th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries presently has an average rating of "Buy" and a consensus target price of $24.13.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA traded up $0.20 during mid-day trading on Friday, hitting $16.76. 8,942,158 shares of the company were exchanged, compared to its average volume of 10,289,327. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80. The company has a debt-to-equity ratio of 2.59, a quick ratio of 0.74 and a current ratio of 1.03. The company has a 50 day moving average of $16.72 and a 200-day moving average of $17.40. The stock has a market cap of $19.22 billion, a price-to-earnings ratio of -14.57, a price-to-earnings-growth ratio of 0.86 and a beta of 0.60.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. During the same quarter in the prior year, the firm earned $0.48 EPS. The company's revenue for the quarter was up 1.9% on a year-over-year basis. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president now owns 9,989 shares in the company, valued at approximately $170,012.78. This represents a 38.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.